Approved for use through 0.73 1/20 12 OMB 055 10031

U.S. Patient and Trademark Outer, U.S. DEPARMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons are required to respond to a collection of information united stigistings and GMB contrib number.

PETI	HON	FOR EXTENSION OF TIME UNDER	Docket Number (Option	Docket Number (Optional)		
	(Fees	FY 2009 pursuant to the Consolidated Appropriations Act,	32U02.1-020	32U02.1-020		
Application Number 10/502,495				Filed 24 JUNE 200	Filed 24 JUNE 2005	
For	For DERMAL APPLICATION SYSTEM FOR AMINOLEVULINIC ACID-DERIVATIVES					
Art Unit 1612				Examiner Maewall,	Examiner Maewall, Snigdha	
This is applic	s a req ation.	uest under the provisions of 37 CFR 1.130	6(a) to extend the p	eriod for filing a reply in the	above identified	
The requested extension and fee are as follows (check time period desired and enter the appropriate fee below);						
			Fee	Small Entity Fee		
		One month (37 CFR 1.17(a)(1))	\$130	\$65	\$	
		Two months (37 CFR 1.17(a)(2))	\$490	\$245	\$	
		Three months (37 CFR 1.17(a)(3))	\$1110	\$555	\$	
		Four months (37 CFR 1.17(a)(4))	\$1730	\$865	\$	
	7	Five months (37 CFR 1.17(a)(5))	\$2350	\$1175	\$ <u>1175.00</u>	
Applicant claims small entity status. See 37 CFR 1.27.						
A check in the amount of the fee is enclosed.						
Payment by credit card. Form PTO-2038 is attached.						
The Director has already been authorized to charge fees in this application to a Deposit Account.						
V I	▼ The Director is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 50-1513 — — — — — — — — — — — — — — — — — — —					
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.						
I am the applicant/inventor.						
assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/96).						
attorney or agent of record. Registration Number 57,896						
attorney or agent under 37 CFR 1.34. Registration number if acting under 37 CFR 1.34.						
	_ Bia_ Ciles			18 December :	18 December 2009	
	Signature				Date	
P	P. Brian Giles			770-984-2300	770-984-2300	
Typed or printed name				Telepho	Telephone Number	
NOTE: signatur	Signatur e is requ	es of all the inventors or assignees of record of the er irred, see below.	tire interest or their repre	sentative(s) are required. Submit	multiple forms if more than one	
Total of 3 forms are submitted.						
his collection of information is required by 37 CFR 1.138(a). The information is required to obtain or retain a benefit by the public which is to file (and by the						

USPT to process an application. Confidentiality is governed by \$5.U.S.C. 122 and 37 CPR 1.1 and 1.14. This collection is estimated to take 8 immutes to complete, including againsting, preparing, and submitting the completed application from the USPT of Time will vary departing upon the individual case. Any comments on the amount of time you require to complete this form endor's suggestions for reducing this bursten, should be sent to the Chief Information Officer. US Department of Commence, P.O. 50s 1440, Alexandrich, VA2 2313-1445, D.O.NOT SEND FEES OR COMMETTED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S. C2(b)(2). (2) furnishing of the information solicited is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal
 agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
 the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(D) or issuance of a patent pursuant to 35 U.S.C. 15(I) or issuance of a patent pursuant to 35 U.S.C. 15(I) or issuance of a patent pursuant to 35 U.S.C. 15(I) or issuance of a patent pursuant to 35 U.S.C. 15(I) or issuance of a patent pursuant to 35 U.S.C. 15(I) or issuance of a patent pursuant to 37 U.S.C. 15(I) or issuance of a patent pursuant to 37 U.S.C. 15(I) or issuance of the public in the public in the public interest pursuant pursu
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.